QTNT News and Press, Quotient Limited From 06/17/22

JERSEY, Channel Islands, June 17, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2022 will be released before market open on Wednesday, June ...

Partnership brings together novel technology and clinical applications expertise to produce automated, multiplexed solutions for advancing autoimmune diagnostics Expands access to $2 billion autoimmune IVD specialty market with MosaiQ Targeted market introduction in the ...

Diversified global presence key to Company's go-to-market strategy Strengthened geographical expansion with distributor strategy model to better support customers in the region JERSEY, Channel Islands, May 17, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercia...

Virtual event on Monday, May 23 rd at 11:00 AM ET The webinar will provide a detailed discussion on the current landscape and unmet needs within blood grouping and donor disease screening JERSEY, Channel Islands, May 12, 2022 (GLOBE NEWSWIRE) -- Quotient Li...

JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's A...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Value has outperformed growth by a substantial margin ove...

JERSEY, Channel Islands, March 21, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced New York Blood Center, Inc. , USA, and Centro de Transfusiones de la Comunidad d...

Quotient (NASDAQ:QTNT) received Conformité Européenne (CE) Mark for its MosaiQ Extended Immunohematology (IH) Microarray. The status allows the company to sell the microarray for use with its MosaiQ instrument across the EU. The company said its MosaiQ platform offers an all-in...

JERSEY, Channel Islands, March 08, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced it has received Conformité Européenne (CE) Mark for its MosaiQ Extended Immu...

JERSEY, Channel Islands, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the Cowen 42nd Annual Health Care Conference. As part of the conference, the Company ...